Friday , November 17 2017
Home / 2016 / November

Monthly Archives: November 2016

PSA: The Prostate Cancer Screening Test

Prostate cancer is the second most common cancer in American men, following skin cancer. One in every seven men will be diagnosed with this form of cancer in his lifetime; with the average age of diagnosis being age 66. In terms of fatalities, only lung cancer comes with a higher …

Read More »

Evotec and Merck KGaA Collaborate for Faster Target Identification Solution

BILLERICA, Mass., Nov. 30, 2016 /PRNewswire/ — Merck, a leading science and technology company, today announced that it has entered into a set of agreements with Evotec AG, whereby Evotec AG will provide screening services for Merck’s collection of genetic reagents such as CRISPR and shRNA libraries. Combining access to …

Read More »

Momenta’s Humira Biosimilar Succeeds in Late-Stage Psoriasis Study

CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA® (adalimumab) candidate developed in collaboration with Baxalta, now part of Shire plc, in patients with moderate-to-severe chronic plaque psoriasis, met its primary endpoint. The proportion …

Read More »

Arrowhead Pharma Halts Work on Lead Hepatitis B Drugs, Focuses on Subcutaneous and Extra-Hepatic RNAi Therapeutics

PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a strategic redeployment of resources to support the development of RNAi therapeutics that utilize the company’s new proprietary subcutaneous (subQ) and extra-hepatic delivery systems. Arrowhead will discontinue development of clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT, which utilize the DPCiv™, …

Read More »

FDA Grants Priority Review to Avelumab for Treatment of Merkel Cell Carcinoma

EMD Serono Inc., the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review EMD Serono’s Biologics License Application (BLA) for avelumab. This review relates to avelumab’s proposed …

Read More »

MedImmune and Abpro Launch AbMed, a Bispecific Antibody Spinout

Gaithersburg, MD and Woburn, MA, November 29, 2016 – MedImmune, the global biologics research and development arm of AstraZeneca, and Abpro, an integrated life sciences company at the forefront of synthetic biology, today announced they have entered into a collaborative agreement to advance the development of a preclinical, novel bispecific …

Read More »

Pfizer’s Investigational Biosimilar to Herceptin Meets Primary Endpoint in Pivotal Trial

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced that the pivotal REFLECTIONS B3271002 study, a comparative safety and efficacy study of PF-05280014 versus Herceptin® (trastuzumab), met its primary endpoint. PF-05280014 is being developed by Pfizer as a potential biosimilar to Herceptin. The trial demonstrated equivalence in the primary endpoint of objective …

Read More »

UT Austin Engineers Develop First-Ever Capsule to Treat Hemophilia

In the near future, hemophiliacs could be able to treat their disease by simply swallowing a capsule. Thanks to a breakthrough led by researchers in the Cockrell School of Engineering at The University of Texas at Austin, treatment for hemophilia can now be administered via a biodegradable system, a capsule, …

Read More »

Gene Discovered to Cause Rare, Severe Neurological Disorder

Researchers have linked a debilitating neurological disease in children to mutations in a gene that regulates neuronal development through control of protein movement within neuronal cells. The scientists from the Montreal Neurological Institute and Hospital at McGill University, led by Peter McPherson, along with collaborators in Saudi Arabia, Jordan, Germany, …

Read More »

FDA Grants Orphan Drug Designation to PhaseRx’s Rare Liver Disorder Drug

SEATTLE, Nov. 28, 2016 /PRNewswire/ — PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that its lead candidate, PRX-OTC, which is being developed for the treatment of ornithine transcarbamylase deficiency (OTCD), has received orphan drug designation by the U.S. …

Read More »